Abstract: The present study was undertaken to identify the congestive heart failure patients by BNP test. To measure BNP levels in Patients with congestive heart disease, to use the BNP in the heart failure treatment and Routine use of BNP assays may help to more rapidly identify patients with heart failure, thereby saving money on unnecessary echocardiograms. In the present study observe the measurement of B-type natriuretic peptide in the heart failure patients.
INTRODUCTION last decade, brain natriuretic peptide (BNP) has emerged
Heart failure, also called congestive heart failure, is a automated rapid assays have been made available condition in which the heart cannot pump enough to hospital laboratories, an increasing number of oxygenated blood to meet the needs of the body's other studies that were performed by clinical investigators organs. The heart keeps pumping, but not as efficiently as have documented the usefulness of these markers in the a healthy heart. Usually, the loss in the heart's pumping process of diagnosis, prognosis and treatment of cardiac action is a symptom of an underlying heart problem. Heart disease [5] . failure affects nearly 35 million adults in world total
The present study was undertaken to identify the population [1] . It is on the rise with an estimated 4 congestive heart failure patients by BNP test.To measure to7 millions new cases each year. More than 7.5 million BNP levels in Patients with congestive heart disease , to Indian's suffer from CHF and nearly a million new use the BNP in the heart failure treatment and Routine use cases arise each year. Congestive heart failure (CHF), of BNP assays may help to more rapidly identify patients congestive cardiac failure (CCF) or just heart failure is a with heart failure, thereby saving money on unnecessary condition that can result from any structural or functional echocardiograms. cardiac disorder that impairs the ability of the heart to fill with or pump a sufficient amount of blood through the MATERIALS AND METHODS body [2] . It is not to be confused with "cessation of heartbeat", which is known as a systole, or with cardiac Population Studies: During the studies at K.G Institution, arrest, which is the cessation of normal cardiac function coimbatore. More than 100 peoples have analyzed, as a with subsequent hemodynamic collapse leading to myocardial symptoms having cases. From this only 80 death [3] . Heart failure may decompensate easily; this abnormal patients have taken out of more than 100 may occur as the result of any intercurrent illness (such patients of both sexes. As these 80 abnormal total as pneumonia), but specifically myocardial infarction patients have been categorized into both males as well as (a heart attack), anemia, hyperthyroidism or arrhythmias.
females based on their various elevated blood BNP levels. These place additional strain on the heart muscle, which According to these 35 female patients were finalized from may cause symptoms to rapidly worsen [4] . During the out of 80 cases. As for the male 45 were identified.
as powerful biochemical markers of cardiac function as 
Standard cal-B 100 29
Standard cal-C 400 116
Standard cal-D 1000 289
Standard cal-E 2000 578S
Tandard cal-F 4000 1156
Preservative, Sodium azide and proclin 300 Asssay Methods for BNP: AxSYM-BNP is a microparticle enzyme immunoassay (MEIA) for the quantitative determination of human B-type natriuretic peptide in human EDTA plasma on the AxSYM system (Photo 1 and 2). BNP values are used as an aid in the diagnosis and assessment of severity of heart failure.
Explanation of the Test:
Numerous studies have indicated that BNP can be used for patient diagnosis, prognosis and therapy monitoring. Levels of BNP have been shown to be elevated in patients with cardiac dysfunction. Plasma BNP levels provide clinically useful information concerning the diagnosis and management of left ventricular dysfunction and heart failure, which complements other diagnostic testing procedures, e.g, electrocardiograms, chest X-rays and echocardiograms. So that BNP is the testing for diagnosis or rule out of heart failure. Plasma BNP levels also increase with decreasing physiological functional capacities, as measured by left ventricular ejection fraction (LVEF). BNP has demonstrated utility for prognostic stratification of patients with heart failure and acute coronary syndromes (ACS). Elevated levels of BNP in heart failure patients predict disease progression and increased morbidity and mortality. Increased BNP levels in ACS patients have a higher rate of cardiac complications and higher post myocardial infraction. Preliminary studies have reported the use of BNP measurements to optimize treatment for hearty failure. Measurements of BNP two hours or more post-treatment detect only the endogenous levels of BNP. Table 2) .
Standardization:
The AxSYM BNP standard Calibrators are traceable to an internal reference standard that has been prepared gravimetrically with synthetic BNP .the internal reference standard underwent a one-time value assignments to align with a commercially available BNP assay with a decision threshold of 100pg/ml.
Specimen Collection and Preparation for Analysis:
EDTA plasma must be used for The AxSYM BNP assay. Other sample types including serum, citrate plasma and heparin plasma arte not recommended. If samples cannot be tested within the given times for room temperature or 2-8°C storage they may be separated by centrifugation and frozen for upto 3 months at -20°C or below in plastic tubes. Multiple freeze / thaw cycles should be avoided. Samples may undergo upto 3 freeze /thaw cycles. Specimens must be mixed thoroughly after thawing, by LOW speed vortexing or by gently inverting and centrifuged prior to use, to remove particulate matter and ensure consistency in the results.
Sample Storage: Whole blood samples, stored at 2-8°C, must be tested within 24 hours of collection.When blood samples, stored at room temperature, must be tested within 4 hours of collection.Plasma samples, stored at 2-8 °C, must be tested within 24 hours of collection.Plasma samples, stored at room temperature, must be tested within 4 hours of collection.
Quality Control: The minimum control requirement for an AxSYM BNP assay is a single sample of all three controls tested every 24 hours. Each day of use for each reagent for controls may be placed in any position in the sample carousel. If the quality controls procedure in the laboratory require more frequent use of controls to verify test results. En sure that assay controls are within the concentration ranges specified in the package insert.
RESULTS
According to the MEIA test procedure, the normal During this project studies, 80 patients were taken as upto 100pg/ml. If the value has been measured above this congestive heart failure having cases. From this affected normal level, which would indicate that patient under the percentage in both sexes have been calculated. This is risk of congestive heart failure. But in these total 80 represented in following Table 3 . From these 45 males and cardiac patients various abnormal blood BNP levels were 35 females marked as congestive heart failure having found. cases in out of total 80 patients. All these 80 patients'
Based on these studies any biochemical marker like blood BNP levels were measured by the instrument of BNP has never been found even at under the normal AxSYS with Microparticle Enzyme Immuno Assay (MEIA) values. In case if peoples were diagnosed with little levels test procedure. Based on these MEIA test procedure, of blood BNP at any age, such a little BNP level would elevated cardiac patients BNP in blood had been analyzed have been taken as a good prognostic tool to treat patient in patients at various age groups and the levels of BNP before affecting with severe conditions of various cardiac mentioned in the unit of pictogram per milliliter. The BNP diseases. Extensively BNP can also be used to identify levels in both sexes are noted separately given in the diabetic patients with cardiac arrest. Table 4 .
Elevation levels of BNP in above aged groups in both DISCUSSION sexes are indicates severity of heart failure.The elevation of blood BNP is not only the myocardial failure but also
The plasma levels of either brain natriuretic peptide with condition that are considered, even which can be one (BNP) has recently gained extreme importance as of reason for patients to have congestive heart failure markers of myocardial dysfunction [6] .The patient has with increased BNP level in the blood. The conditions normal systolic function but symptoms consistent with included are such as cigarette smoking, alcohol intake, cardiac failure and a clearly raised brain natriuretic hypertension and high intakes of non-veg items. These peptide level, diastolic heart failure is likely to be present. are marked in the percentage order given in the Table 5 .
If our pilot findings are corroborated both in systolic Table 3 : Table 5 : levels of BNP in heart failure patient's blood would be and diastolic dysfunction, it is probable that a set of target levels of plasma BNP can be established to guide treatment of systolic and diastolic dysfunction within both sexes (plasma BNP is higher in females) and in different age groups (brain natriuretic peptide rises with age) [7] . A BNP level of 80 pg/ml is useful in diagnosing heart failure in symptomatic patients without a history of heart failure. BNP levels are potentially more useful when a baseline concentration is known for a patient, because BNP levels are proportional to the severity of heart failure. Maintaining a BNP concentration of less than 100 pg/ml has shown to correlate with functional improvement in patients with heart failure and has tended to decrease clinical endpoints, such as cardiovascular death. Consequently, using BNP concentrations to monitor patients with heart failure and manage their medical therapy accordingly might improve overall morbidity and mortality [8] .
The Measurements of B-type natriuretic peptide added significant independent predictive power to other clinical variables in models predicting which patients had congestive heart failure. Rapid measurement of B-type natriuretic peptide is useful in establishing or excluding the diagnosis of congestive heart failure in patients [9] . Cardiac Resynchronization -Heart Failure (CARE-HF) levels of ANP and BNP have been found to be increased Study Investigators. "The effect of cardiac in patients with various heart diseases, but the elevation resynchronization on morbidity and mortality in heart in circulatory BNP correlates better than ANP with the failure". N Engl J. Med. (15): 1539-49. severity of CHF. Therefore, plasma BNP has been 5. James, S.K., B. Lindahl and A. Siegbahn, 2003. suggested (and lately used) to aid in the accurate N-terminal pro-brain natriuretic peptide and other risk diagnosis of heart failure in patients admitted to the markers for the separate prediction of mortality and emergency room with symptoms of decompensate heart subsequent myocardial infarction in patients with failure. Furthermore, circulatory BNP has been utilized as unstable coronary artery disease: a Global Utilization a prognostic marker in CHF as well as a hormone guide in
of Strategies to open occluded arteries (GUSTO)-IV the evaluation of the efficacy of the conventional sub study. Circulation, 108: 275-281. treatment of this disease state.
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